Yixin Yao

7PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 09, 2026
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.

|Apr 08, 2026
Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

Yuxuan Che, Yang Liu, Yixin Yao

|Nov 03, 2023
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.

Yijing Li, Heng-Huan Lee, Vivian Changying Jiang

|Feb 16, 2023
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

Yuxuan Che, Yang Liu, Yixin Yao

|Nov 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.

Preetesh Jain, Shuangtao Zhao, Hun Ju Lee

|Nov 30, 2019
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.

Jeffrey Wang, Jacqueline Wang, Elyse Lopez

Pageof 2

Frequent Collaborators

7 joint publications

Michael Wang

6 joint publications

Yang Liu

3 joint publications

Holly A Hill

3 joint publications

Preetesh Jain